Practical Patient Care Weekly
Practical Patient Care
Your one stop, leading multi-platform news source for the global healthcare sector.
Welcome to another edition of the Practical Patient Care newsletter!
Discover the latest insights and analyses from the global healthcare market over the past week, brought to you by Practical Patient Care
Hearst , the diversified information and media giant, is set to acquire QGenda , a leading provider of healthcare workforce management solutions. This strategic move will bolster Hearst's healthcare division, Hearst Health.
Greg Benoit, QGenda's founder and CEO, expressed enthusiasm: "The entire QGenda team is proud and excited for the opportunity to be part of Hearst Health."QGenda's ProviderCloud platform, serving over 700,000 healthcare providers, will now be part of Hearst's arsenal.
Gregory Dorn, Hearst Health president, highlighted the acquisition's significance: "At a time of clinician shortages, the QGenda platform meets a critical need for organisations looking to optimise clinical team deployment."
Caresyntax , a Germany-based precision surgery platform, has secured $180 million in a Series C extension round to advance AI-enabled surgery.
The funding comprises $80 million in equity and up to $100 million in growth debt facility. Caresyntax plans to use this capital to scale customer adoption of its surgical software tools, continue developing AI and cloud applications, and support its mergers and acquisitions strategy.
The investment round saw participation from various investors, including Symbiotic Capital, MTIP, BIONIQ Capital, and surgical.ai, among others. This financing comes at a crucial time for the adoption of digital surgery, AI, and automation tools in healthcare. Caresyntax's platform leverages technology and AI to collect, integrate, and analyse comprehensive surgical data, providing real-time and long-term clinical decision support to caregivers.
The company aims to enhance patient outcomes, increase hospital operational efficiency, and drive profitability in the global surgical market.
"This financing is not just an investment in Caresyntax, but an investment in the future of surgery," said Dennis Kogan, co-founder and CEO of Caresyntax, highlighting the potential impact of their AI-powered surgical tools on patient outcomes.
Cresilon has achieved a significant milestone by securing FDA approval for Traumagel, an innovative hemostatic gel designed to rapidly control moderate to severe bleeding.
This plant-based gel can stop life-threatening bleeding within seconds when applied to wounds, utilizing Cresilon's proprietary hydrogel technology. Supplied in pre-filled syringes, Traumagel requires no preparation for easy application.
The FDA granted 510(k) clearance for Traumagel's temporary external use, and Cresilon plans to develop it for the U.S. military, government health agencies, emergency medical services, and clinicians dealing with traumatic wounds.
This marks Cresilon's second FDA clearance, following the approval of their Hemostatic Gel for minor wounds in 2023. The company expects to launch Traumagel strategically in late 2024.
Cresilon CEO and co-founder Joe Landolina stated, “The ability to rapidly stop bleeding at the point of care and halt a life-threatening hemorrhage can be the difference between life and death for people with traumatic wounds.”In addition to this achievement, Cresilon is researching the gel's potential for treating traumatic brain injuries, representing a significant advancement in trauma care and offering a rapid and effective solution for controlling severe bleeding in emergency situations.
MolecuLight 's ground-breaking imaging technology is making waves in wound care, promoting health equity and improving patient outcomes across diverse populations.
领英推荐
The company's fluorescence imaging devices can detect harmful bacteria in wounds instantly, regardless of a patient's skin tone.
This innovation addresses a critical gap in medical training and practice. As Dr. Charles Andersen, lead author of a recent publication on the topic, explains: "Medical curricula have historically failed to equip wound care clinicians with the knowledge and skills to accurately identify signs of infection on dark skin".
MolecuLight's technology provides an objective tool that overcomes this limitation. The impact on health equity is significant. Dr. Jonathan Johnson, study co-author and health equity advocate, states: "There are now technologies that can identify more Black patients with wound infections who can be treated more efficaciously to prevent infection complications including gangrene, sepsis, and amputations".
MolecuLight's CEO, Anil Amlani, emphasizes the company's commitment: "We aim to make MolecuLight technology as accessible as possible and to reduce the health equity gap".
This technology represents a crucial step towards more equitable wound care, especially for marginalized populations who often face reduced access to quality healthcare.
Exciting news in the medical technology world! Stryker, a leading global medical technology company, has announced its agreement to acquire care.ai, a provider of AI-assisted virtual care workflows and smart room technology.
Andy Pierce's Group President of MedSurg and Neurotechnology, emphasized the strategic importance of this move: "care.ai will help Stryker significantly accelerate our healthcare IT and digital vision to provide customers with real-time, smart and connected decision-making tools that enhance the lives of caregivers and their patients."
This acquisition aims to strengthen Stryker's healthcare IT offerings and integrate seamlessly with its Vocera platform. The deal addresses critical industry challenges like nursing shortages and workplace safety concerns, potentially revolutionizing patient care delivery.
Halifax Health in Volusia County has become the first facility in the US to utilize the Accuray Radixact Radiation Delivery System with VitalHold technology.
This ground-breaking treatment is now available at the Charles L. and Miki N. Grant Cancer Center for Hope in Port Orange.
The Radixact System, enhanced with ClearRT helical CT imaging and Synchrony real-time adaptive delivery technologies, offers precise and efficient cancer treatment.
Accuray's President and CEO, Suzanne Winter, states, "The Radixact System is designed to offer certainty in every step of the treatment process, from simulation through radiation delivery, to facilitate high-quality cancer care today while also providing a platform able to evolve with continued innovation."
Halifax Health President and CEO Jeff Feasel adds, "As the first and only centre in the US to treat cancer using the Radixact System and VitalHold, we are demonstrating our commitment to providing the highest level of care to the people in our community."
This advancement marks a significant milestone in cancer treatment, offering patients in Florida access to cutting-edge radiotherapy technology
To have a story featured on next week's newsletter, or require press and marketing support you can contact our team directly...
Editorial Enquiries - [email protected]
Press & Marketing support - [email protected]
Thanks for reading; we hope you enjoyed it.
Until next week.